FibroGen

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

FibroGen reports improved financials and readies for new therapy launches

FibroGen's financials improved in Q4 2022, with strong cash reserves.
Strategic focus on new therapy launches and pivotal Phase 3 data.
Progress in commercial manufacturing and readiness for potential launches.
Emphasis on FDA feedback for filing strategies and multiple efficacy endpoints.

FibroGen reports Q1 revenue growth, faces challenges in study results

FibroGen's Q1 2023 performance showed strong revenue but faced challenges with roxadustat's Phase 3 study results.
The company's strengths lie in commercial opportunities, financial stability, and adherence to rigorous data analysis methods.
Challenges include addressing study result concerns and uncertainties in funding tied to clinical milestones.
Opportunities exist in market expansion, especially in IPF treatment, and upcoming Phase 3 trials for pamrevlumab.

FibroGen reports revenue growth amidst challenges and promising opportunities

FibroGen's Q2 2023 performance showed revenue growth and cost reduction efforts.
The company faces challenges in pamrevlumab trials and patent validity issues in China.
However, opportunities lie in upcoming trial readouts and the early-stage oncology pipeline.
FibroGen's strategic pillars and commitment to cost savings are key strengths.

FibroGen reports robust Q3 earnings, eyes expansion amid market challenges

FibroGen's Q3 performance was strong, driven by revenue growth and promising trial results.
The company's strategic pillars and clear pricing strategies position it well for future growth.
While facing challenges like generic competition, FibroGen has opportunities for expansion and market differentiation.
Overall, FibroGen's financial health and pipeline developments indicate a positive outlook for the company.

FibroGen reports robust Q4 performance and eyes expansion opportunities

FibroGen's Q4 2023 earnings call showcased strong performance in China for roxadustat and provided a detailed financial update, addressing key inquiries from analysts.
The company's strategic pillars, emphasis on highest tolerable doses for efficacy, and promising Phase I results position FibroGen well for future growth and drug development.
While challenges exist in interpreting data and prioritizing studies, opportunities in expanding market reach, refining development strategies, and enhancing efficacy markers are evident.
Overall, FibroGen's proactive approach to addressing challenges and exploring opportunities underscores a commitment to innovation and growth in the pharmaceutical sector.

FibroGen reports robust earnings, eyes growth in China and oncology

FibroGen's Q1 2024 earnings call highlighted strong financial performance, promising drug developments, cost efficiencies, and strategic focus on future growth. Despite challenges like market competition and regulatory timelines, the company remains optimistic and proactive in pursuing opportunities for expansion.

FibroGen reports strong Q3 performance in China, eyes growth

FibroGen's Q3 2024 results reflect notable growth in Roxadustat sales in China, cost reductions, and improved financial performance, positioning the company for future success.
Despite facing challenges such as expense management and market uncertainties, FibroGen's strategic pillars, positive outlook, and cash reserves offer resilience and growth potential.
Opportunities lie in market expansion, innovation, and partnerships, signaling a promising trajectory for FibroGen to capitalize on its strengths and drive value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

SAN FRANCISCO and TOKYO, Sept.  20, 2019  (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A. Schoeneck, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Evrenzo® (generic name: roxadustat; tradename Evrenzo® in Japan) for the treatment of anemia associated with chronic kidney disease (CKD) in dialysis patients.

Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

BioSpecifics Technologies

Endo International

Vaxart

Endo International (ENDP) files BLA for collagenase clostridium histolyticum (CCH) for the treatment of cellulite in the buttocks.

Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)

FibroGen (FGEN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

FibroGen (FGEN) Catches Eye: Stock Jumps 7.4%

FibroGen Inc. (NASDAQ: FGEN) shares dipped slightly on Monday after the firm announced the passing of its chief executive and board chair, Thomas B.

Fibrogen Announces Passing of CEO

SAN FRANCISCO, Aug.  26, 2019  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced today that Thomas B. Neff, Chief Executive Officer and Chairman of the Board of Directors of FibroGen, passed away unexpectedly this past weekend.

Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive

SAN FRANCISCO, Aug.  21, 2019  (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the National Medical Products Administration (NMPA) in China has approved expansion of the marketing authorization of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anemia caused by chronic kidney disease (CKD) to include treatment in CKD patients who are not dialysis-dependent (NDD).

Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis

CEO of Fibrogen Inc (30-Year Financial, Insider Trades) Thomas B Neff (insider trades) sold 39,636 shares of FGEN on 08/13/2019 at an average price of $45.44 a share.

Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares

FibroGen, Inc. (FGEN) CEO Tom Neff on Q2 2019 Results - Earnings Call Transcript

FibroGen (FGEN) delivered earnings and revenue surprises of 357.14% and 492.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Q2 Earnings and Revenues Top Estimates

CEO of Fibrogen Inc (30-Year Financial, Insider Trades) Thomas B Neff (insider trades) sold 39,636 shares of FGEN on 07/25/2019 at an average price of $46.74 a share.

Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.9 million of Shares

Salesforce

Alphabet

Haemonetics

More and more, the companies that we cover on Wall Street are starting to agree that while the future’s still bright for the U.S.

Jefferies Analysts Are Out With Four Daring Summer Growth Stock Picks

FibroGen’s stock price recently experienced a big drop after the release of its Phase III MACE result.

FibroGen's Roxadustat Shows A Clear Positive Phase III MACE Result, But Future Sales Remain Uncertain

Investors need to pay close attention to FibroGen (FGEN) stock based on the movements in the options market lately.

Implied Volatility Surging for FibroGen (FGEN) Stock Options

The company reported confusing top-line results from an important batch of phase 3 safety studies. Were they successful?

Here's Why FibroGen Fell as Much as 26.6% Today

FibroGen news has FGEN stock down on Friday after releasing confusing results from a recent trial for its kidney disease drug.

FibroGen News: Why FGEN Stock Is Plummeting Today

FibroGen's (FGEN) CEO Tom Neff on Q1 2019 Results - Earnings Call Transcript

FibroGen (FGEN) needs investors to pay close attention to the stock based on moves in the options market lately.

Options Traders Expect Huge Moves in FibroGen (FGEN) Stock

Assembly Biosciences

GW Pharmaceuticals

Heron Therapeutics

April's about to shower biopharma investors with important updates that could move these stocks.

Biotech Stocks With Major Catalysts in April

FibroGen has major catalysts this year. After years of extensive trialing, its lead drug roxadustat will have its date with the FDA probably later this year.

News for FibroGen Stock (FGEN)